Berlex Foundation Seeks Workshop Applicants

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

DUMONT, NJ--The Berlex On-cology Foundation is seeking applicants for two workshops: Epidemiology and Clinical Trial Design, to be held August 23-29, 1996, in Brewster, Mass, and The Clinical Pharmacology of Anticancer Drugs, which will take place October 4-8, 1996, in Leesburg, Va.

DUMONT, NJ--The Berlex On-cology Foundation is seeking applicantsfor two workshops: Epidemiology and Clinical Trial Design, tobe held August 23-29, 1996, in Brewster, Mass, and The ClinicalPharmacology of Anticancer Drugs, which will take place October4-8, 1996, in Leesburg, Va.

Aimed at young investigators interested in cancer research, theinteractive workshops offer ample opportunity for one-on-one interfacingwith the faculty, as well as peer-to-peer networking.

The awards cover travel expenses, lodging, meals, course syllabus,and textbooks. The application deadlines are May 30, 1996, forthe epidemiology workshop, and June 30, 1996, for the anticancerdrugs course. Twenty scholars will be selected for each program.

All applicants must be currently enrolled in an accredited oncologytraining program and should possess a demonstrated interest incancer research. Applicants must supply a current curriculum vitae,letter of recommendation from the department chairman, and a one-pageletter describing the applicant's purpose in attending the program.

For more information, contact Svetlana Lisanti, Berlex OncologyFoundation, 80 W. Madison Ave., Dumont, NJ 07628, or telephone201-385-0006.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content